Histone deacetylase inhibitors: An attractive strategy for cancer therapy

Current Medicinal Chemistry

Volumn 20, Issue 14, 2013, Pages 1858-1886

  Li, Jiyang ^a   Li, Guangqiang ^a   Xu, Wenqing ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Antitumor drugs; Cancer therapy; Cyclic peptide; Drug discovery; Epigenetic regulation; Hdac isoforms; Histone deacetylase; Histone deacetylase inhibitors; Hybrid compounds; Multi targeted inhibitor

Indexed keywords

ABEXINOSTAT; ACY 1215; ANTINEOPLASTIC AGENT; AR 42; BELINOSTAT; BML 210; BYK 408740; CHR 3996; CUDC 101; DACINOSTAT; ENTINOSTAT; ETOPOSIDE; FR 235222; GIVINOSTAT; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROLASE; M 344; MOCETINOSTAT; NSC 696085; PANOBINOSTAT; PCI 34051; QUISINOSTAT; R 306465; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SB 939; SHP 141; SK 7041; TACEDINALINE; TAMOXIFEN; TEFINOSTAT; THIOREDOXIN; TUBACIN; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOPLASM; DEACETYLATION; DNA DAMAGE; DRUG ABSORPTION; DRUG DESIGN; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; HISTONE ACETYLATION; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UBIQUITINATION;

ANIMALS; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878002317     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320140005     Document Type: Article

References (134)

1. Kornberg, R. D.; Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell, 1999, 98 (3), 285-94 (Pubitemid 29380564)
2. Shahbazian, M. D.; Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem., 2007, 76, 75-100
3. Pazin, M. J.; Kadonaga, J. T. What's up and down with histone deacetylation and transcription? Cell, 1997, 89 (3), 325-8 (Pubitemid 27220876)
4. Marmorstein, R.; Roth, S. Y. Histone acetyltransferases: Function, structure, and catalysis. Curr. Opin. Genet. Dev., 2001, 11 (2), 155-161 (Pubitemid 32209199)
5. Dekker, F. J.; Haisma, H. J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today, 2009, 14 (19), 942-948
6. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov, 2006, 5 (1), 37-50
7. Gallinari, P.; Di Marco, S.; Jones, P.; Pallaoro, M.; Steinkuhler, C. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res., 2007, 17 (3), 195-211 (Pubitemid 46438722)
8. Palani, C. D.; Beck, J. F.; Sonnemann, J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Investigational New Drugs-Journal of Anti Cancer Agents, 2012, 30 (1), 25
9. Spange, S.; Wagner, T.; Heinzel, T.; Krämer, O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. The international journal of biochemistry & cell biology, 2009, 41 (1), 185
10. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417 (6887), 455-458 (Pubitemid 34563539)
11. Zhang, Y.; Fang, H.; Jiao, J.; Xu, W. The structure and function of histone deacetylases: The target for anti-cancer therapy. Curr. Med. Chem., 2008, 15 (27), 2840-9
12. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat Rev Mol Cell Biol, 2008, 9 (3), 206-18 (Pubitemid 351301825)
13. Marks, P. A.; Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107 (4), 600-8
14. Olmos, Y.; Brosens, J. J.; Lam, E. W. F. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resistance Updates, 2011, 14 (1), 35-44
15. Prompers, L.; Bucerius, J.; Brans, B.; Temur, Y.; Berger, L.; Mottaghy, F. M. Selective internal radiation therapy (SIRT) in primary or secondary liver cancer. Methods, 2011, 55 (3), 253-257
16. Stünkel, W.; Campbell, R. M. Sirtuin 1 (SIRT1) The Misunderstood HDAC. J. Biomol. Screen., 2011, 16 (10), 1153-1169
17. Atadja, P. W. HDAC inhibitors and cancer therapy. Prog. Drug Res., 2011, 67, 175-95
18. Weichert, W.; Röske, A.; Niesporek, S.; Noske, A.; Buckendahl, A. C.; Dietel, M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res., 2008, 14 (6), 1669-1677 (Pubitemid 351469450)
19. Fritzsche, F. R.; Weichert, W.; Röske, A.; Gekeler, V.; Beckers, T.; Stephan, C.; Jung, K.; Scholman, K.; Denkert, C.; Dietel, M. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer, 2008, 8 (1), 381
20. Weichert, W.; Denkert, C.; Noske, A. Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. Neoplasia, 2008, 10, 1021-1027
21. Weichert, W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett., 2009, 280 (2), 168-176
22. Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeir, R.; Jenuwein, T. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. The EMBO journal, 2002, 21 (11), 2672-2681 (Pubitemid 34619383)
23. Montgomery, R. L.; Davis, C. A.; Potthoff, M. J.; Haberland, M.; Fielitz, J.; Qi, X.; Hill, J. A.; Richardson, J. A.; Olson, E. N. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev., 2007, 21 (14), 1790-1802 (Pubitemid 47076478)
24. Ito, A.; Kawaguchi, Y.; Lai, C. H.; Kovacs, J. J.; Higashimoto, Y.; Appella, E.; Yao, T. P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. The EMBO journal, 2002, 21 (22), 6236-6245 (Pubitemid 35415340)
25. Senese, S.; Zaragoza, K.; Minardi, S.; Muradore, I.; Ronzoni, S.; Passafaro, A.; Bernard, L.; Draetta, G. F.; Alcalay, M.; Seiser, C. Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol., 2007, 27 (13), 4784-4795 (Pubitemid 47016131)
26. Marson, C. M. Histone deacetylase inhibitors: Design, structureactivity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem, 2009, 9 (6), 661-92
27. Zhu, P.; Huber, E.; Kiefer, F.; Gottlicher, M. Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle, 2004, 3 (10), 1240-2 (Pubitemid 40268601)
28. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R. Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun., 2003, 310 (2), 529-36 (Pubitemid 37163696)
29. Li, Y.; Kao, G. D.; Garcia, B. A.; Shabanowitz, J.; Hunt, D. F.; Qin, J.; Phelan, C.; Lazar, M. A. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev., 2006, 20 (18), 2566-2579 (Pubitemid 44396841)
30. Bhaskara, S.; Chyla, B. J.; Amann, J. M.; Knutson, S. K.; Cortez, D.; Sun, Z. W.; Hiebert, S. W.; Chyla, B.; Amann, J. Deletion of Histone Deacetylase 3 reveals critical roles in S-phase progression and DNA damage control. Mol. Cell, 2008, 30 (1), 61
31. Montgomery, R. L.; Potthoff, M. J.; Haberland, M.; Qi, X.; Matsuzaki, S.; Humphries, K. M.; Richardson, J. A.; Bassel-Duby, R.; Olson, E. N. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest., 2008, 118 (11), 3588
32. Balasubramanian, S.; Verner, E.; Buggy, J. J. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett., 2009, 280 (2), 211-221
33. Wedel, T.; Van Eys, G.; Waltregny, D.; Glenisson, W.; Castronovo, V.; Vanderwinden, J. Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders. Neurogastroenterol. Motil., 2006, 18 (7), 526-538 (Pubitemid 43855806)
34. Oehme, I.; Deubzer, H. E.; Wegener, D.; Pickert, D.; Linke, J. P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S. M.; von Deimling, A.; Fischer, M.; Witt, O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res., 2009, 15 (1), 91-9
35. De Leval, L.; Waltregny, D.; Boniver, J.; Young, R. H.; Castronovo, V.; Oliva, E. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. The American journal of surgical pathology, 2006, 30 (3), 319-327 (Pubitemid 43740163)
36. Oehme, I.; Deubzer, H. E.; Lodrini, M.; Milde, T.; Witt, O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert opinion on investigational drugs, 2009, 18 (11), 1605-1617
37. Vega, R. B.; Matsuda, K.; Oh, J.; Barbosa, A. C.; Yang, X.; Meadows, E.; McAnally, J.; Pomajzl, C.; Shelton, J. M.; Richardson, J. A. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell, 2004, 119 (4), 555-566 (Pubitemid 39482354)
38. Chauchereau, A.; Mathieu, M.; de Saintignon, J.; Ferreira, R.; Pritchard, L. L.; Mishal, Z.; Dejean, A.; Harel-Bellan, A. HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene, 2004, 23 (54), 8777-8784 (Pubitemid 39593292)
39. Bolger, T. A.; Yao, T. P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci., 2005, 25 (41), 9544-53 (Pubitemid 41464769)
40. Chang, S.; McKinsey, T. A.; Zhang, C. L.; Richardson, J. A.; Hill, J. A.; Olson, E. N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol., 2004, 24 (19), 8467-8476 (Pubitemid 39245069)
41. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 2002, 110 (4), 479-488 (Pubitemid 35232291)
42. Dequiedt, F.; Kasler, H.; Fischle, W.; Kiermer, V.; Weinstein, M.; Herndier, B. G.; Verdin, E. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCRmediated apoptosis. Immunity, 2003, 18 (5), 687
43. Chang, S.; Young, B. D.; Li, S.; Qi, X.; Richardson, J. A.; Olson, E. N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell, 2006, 126 (2), 321-334 (Pubitemid 44092958)
44. Zhu, C.; Chen, Q.; Xie, Z.; Ai, J.; Tong, L.; Ding, J.; Geng, M. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: Regulation on c-Myc. J Mol Med (Berl), 2011, 89 (3), 279-89
45. Zhang, G.; Wang, Z. [RNA interference of HDAC7 expression in hepatocellular carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2010, 35 (7), 718-24
46. Zhang, Y.; Kwon, S. H.; Yamaguchi, T.; Cubizolles, F.; Rousseaux, S.; Kneissel, M.; Cao, C.; Li, N.; Cheng, H. L.; Chua, K. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol., 2008, 28 (5), 1688-1701
47. Kekatpure, V. D.; Dannenberg, A. J.; Subbaramaiah, K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem., 2009, 284 (12), 7436-7445
48. Zhang, Z.; Yamashita, H.; Toyama, T.; Sugiura, H.; Omoto, Y.; Ando, Y.; Mita, K.; Hamaguchi, M.; Hayashi, S.; Iwase, H. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res., 2004, 10 (20), 6962-6968 (Pubitemid 39383047)
49. Aldana-Masangkay, G. I.; Sakamoto, K. M. The role of HDAC6 in cancer. J. Biomed. Biotechnol., 2010, 2011,
50. Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proceedings of the National Academy of Sciences, 2010, 107 (46), 20003-20008
51. Lee, J.-H.; Jeong, E.-G.; Choi, M.-C.; Kim, S.-H.; Park, J.-H.; Song, S.-H.; Park, J.; Bang, Y.-J.; Kim, T.-Y. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol. Cells, 2010, 30 (2), 107-112
52. Buglio, D.; Khaskhely, N. M.; Voo, K. S.; Martinez-Valdez, H.; Liu, Y. J.; Younes, A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood, 2011, 117 (10), 2910-2917
53. Villagra, A.; Cheng, F.; Wang, H. W.; Suarez, I.; Glozak, M.; Maurin, M.; Nguyen, D.; Wright, K. L.; Atadja, P. W.; Bhalla, K. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol., 2008, 10 (1), 92-100
54. Guenther, M. G.; Barak, O.; Lazar, M. A. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol., 2001, 21 (18), 6091-101 (Pubitemid 34263509)
55. Fischle, W.; Dequiedt, F.; Hendzel, M. J.; Guenther, M. G.; Lazar, M. A.; Voelter, W.; Verdin, E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell, 2002, 9 (1), 45-57 (Pubitemid 34127770)
56. Qian, D. Z.; Kachhap, S. K.; Collis, S. J.; Verheul, H. M. W.; Carducci, M. A.; Atadja, P.; Pili, R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxiainducible factor 1α. Cancer Res., 2006, 66 (17), 8814-8821 (Pubitemid 44449199)
57. Robert, T.; Vanoli, F.; Chiolo, I.; Shubassi, G.; Bernstein, K. A.; Rothstein, R.; Botrugno, O. A.; Parazzoli, D.; Oldani, A.; Minucci, S.; Foiani, M. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature, 2011, 471 (7336), 74-79
58. Shabason, J. E.; Tofilon, P. J.; Camphausen, K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J. Cell. Mol. Med., 2011, 15 (12), 2735-2744
59. Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol. Cell Biol., 2011,
60. Wagner, J. M.; Hackanson, B.; Lübbert, M.; Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical epigenetics, 2010, 1 (3), 117-136
61. Marks, P.; Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107 (4), 600-608
62. Ganesan, A.; Nolan, L.; Crabb, S.; Packham, G. Epigenetic therapy: Histone acetylation, DNA methylation and anticancer drug discovery. Curr. Cancer Drug Targets, 2009, 9 (8), 963
63. Prince, H. M.; Bishton, M. J.; Harrison, S. J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res., 2009, 15 (12), 3958-3969
64. Available from: Http://www.fda.gov/default.htm.
65. Ellis, L.; Bots, M.; Lindemann, R. K.; Bolden, J. E.; Newbold, A.; Cluse, L. A.; Scott, C. L.; Strasser, A.; Atadja, P.; Lowe, S. W. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood, 2009, 114 (2), 380-393
66. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: From bench to clinic. J. Med. Chem., 2008, 51 (6), 1505-29 (Pubitemid 351438836)
67. http://www.4sc.de/.
68. Available from: Http://www.clinicaltrials.gov/.
69. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22 (5), 1026-34 (Pubitemid 351689885)
70. Stühmer, T.; Arts, J.; Chatterjee, M.; Borawski, J.; Wolff, A.; King, P.; Einsele, H.; Leo, E.; Bargou, R. C. Preclinical anti?myeloma activity of the novel HDAC?inhibitor JNJ?26481585. Br. J. Haematol., 2010, 149 (4), 529-536
71. Razak, A. R. A.; Hotte, S.; Siu, L.; Chen, E.; Hirte, H.; Powers, J.; Walsh, W.; Stayner, L.; Laughlin, A.; Novotny-Diermayr, V. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer, 2011, 104 (5), 756-762
72. Santo, L.; Hideshima, T.; Kung, A. L.; Tseng, J. C.; Tamang, D.; Yang, M.; Jarpe, M.; van Duzer, J. H.; Mazitschek, R.; Ogier, W. C.; Cirstea, D.; Rodig, S.; Eda, H.; Scullen, T.; Canavese, M.; Bradner, J.; Anderson, K. C.; Jones, S. S.; Raje, N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 2012, 119 (11), 2579-89
73. Moffat, D.; Patel, S.; Day, F.; Belfield, A.; Donald, A.; Rowlands, M.; Wibawa, J.; Brotherton, D.; Stimson, L.; Clark, V. Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl) methyl] amino} bicyclo [3.1. 0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. J. Med. Chem., 2010, 53 (24), 8663-8678
74. https://ash.confex.com/ash/2010/webprogram/Paper28495.html.
75. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst-detail-view&confID=65&abstractID=33621.
76. Banerji, U.; van Doorn, L.; Papadatos-Pastos, D.; Kristeleit, R.; Debnam, P.; Tall, M.; Stewart, A.; Raynaud, F.; Garrett, M. D.; Toal, M. A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clin. Cancer Res., 2012, 18 (9), 2687-2694
77. http://clinicaltrials.gov/ct2/show/NCT00820508.
78. Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; Van Dun, J.; Janssen, L.; Geerts, T.; Tuman, R. R306465 is a novel potent inhibitor of class I histone deacetylases with broadspectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer, 2007, 97 (10), 1344-1353 (Pubitemid 350114783)
79. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.-J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-Ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer. J. Med. Chem., 2010, 53 (5), 2000-2009
80. Lai, C. J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D. G.; Yin, L.; Samson, M.; Forrester, J. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 2010, 70 (9), 3647-3656
81. Jacob, A.; Oblinger, J.; Bush, M. L.; Brendel, V.; Santarelli, G.; Chaudhury, A. R.; Kulp, S.; La Perle, K.; Chen, C. S.; Chang, L. S. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope, 2012,
82. Zimmerman, B.; Sargeant, A.; Landes, K.; Fernandez, S. A.; Chen, C. S.; Lairmore, M. D. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk. Res., 2011, 35 (11), 1491-1497
83. Available from: Http://clinicaltrials.gov/ct2/show/NCT01433731?term= shp141&rank=1.
84. Petrella, A.; D'Acunto, C. W.; Rodriquez, M.; Festa, M.; Tosco, A.; Bruno, I.; Terracciano, S.; Taddei, M.; Paloma, L. G.; Parente, L. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of annexin A1. Eur. J. Cancer, 2008, 44 (5), 740-749
85. Rodriquez, M.; Terracciano, S.; Cini, E.; Settembrini, G.; Bruno, I.; Bifulco, G.; Taddei, M.; Gomez-Paloma, L. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angew. Chem., 2005, 118 (3), 437-441
86. Terracciano, S.; Di Micco, S.; Bifulco, G.; Gallinari, P.; Riccio, R.; Bruno, I. Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. Bioorg. Med. Chem., 2010, 18 (9), 3252-60
87. Ryu, J. K.; Lee, W. J.; Lee, K. H.; Hwang, J. H.; Kim, Y. T.; Yoon, Y. B.; Kim, C. Y. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett., 2006, 237 (1), 143
88. Lee, K.; Kim, J.; Park, J.; Kim, H.; Song, S.; Kim, S.; Kim, T.; Jong, H.; Jung, K.; Im, S. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res., 2006, 26 (5A), 3429-3438 (Pubitemid 44701519)
89. KIM, I. A.; KIM, I. H.; KIM, H. J.; CHIE, E. K.; KIM, J. S. HDAC Inhibitor-Mediated Radiosensitization in Human Carcinoma Cells: A General Phenomenon? J. Radiat. Res. (Tokyo). 2010, 51 (3), 257-263
90. Konsoula, Z.; Velena, A.; Lee, R.; Dritschilo, A.; Jung, M. Histone deacetylase inhibitor: Antineoplastic agent and radiation modulator. Human Cell Transformation, 2012, 171-179
91. Krige, D.; Needham, L. A.; Bawden, L. J.; Flores, N.; Farmer, H.; Miles, L. E. C.; Stone, E.; Callaghan, J.; Chandler, S.; Clark, V. L. CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res., 2008, 68 (16), 6669-6679
92. Jenkins, C.; Hewamana, S.; Krige, D.; Pepper, C.; Burnett, A. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leuk. Res., 2011, 35 (5), 677-681
93. Wang, H.; Dymock, B. W. New patented histone deacetylase inhibitors. Expert. Opin. Ther. Pat., 2009, 19 (12), 1727-57
94. Wightman, F.; Ellenberg, P.; Churchill, M.; Lewin, S. R. HDAC inhibitors in HIV. Immunol. Cell Biol., 2011,
95. Andrews, K. T.; Haque, A.; Jones, M. K. HDAC inhibitors in parasitic diseases. Immunol. Cell Biol., 2011, 90 (1), 66-77
96. Adcock, I. HDAC inhibitors as anti?inflammatory agents. Br. J. Pharmacol., 2007, 150 (7), 829-831
97. Shah, M. H.; Villalona-Calero, M. A.; Marcucci, G.; Byrd, J. C.; Grever, M. R. HDAC inhibitors and cardiac safety. Clin. Cancer Res., 2007, 13 (3), 1068-1068
98. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401 (6749), 188-193 (Pubitemid 29436325)
99. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfí, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO reports, 2007, 8 (9), 879-884 (Pubitemid 350001433)
100. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 2004, 12 (7), 1325-1334 (Pubitemid 38900774)
101. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 2008, 283 (17), 11355-11363
102. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol., 2005, 354 (1), 107-20 (Pubitemid 41527217)
103. Bottomley, M. J.; Surdo, P. L.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkühler, C. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem., 2008, 283 (39), 26694-26704
104. Bressi, J.; Jennings, A.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C.; Navre, M.; Gangloff, A. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl) benzamides. Bioorg. Med. Chem. Lett., 2010, 20 (10), 3142-3145
105. Lombardi, P. M.; Angell, H. D.; Whittington, D. A.; Flynn, E. F.; Rajashankar, K. R.; Christianson, D. W. Structure of prokaryotic polyamine deacetylase reveals evolutionary functional relationships with eukaryotic histone deacetylases. Biochem. (Mosc)., 2011, 50 (11), 1808-17
106. Weerasinghe, S. V.; Estiu, G.; Wiest, O.; Pflum, M. K. Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: Implications for designing isoform-selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51 (18), 5542-51
107. Wu, R.; Lu, Z.; Cao, Z.; Zhang, Y. Zinc Chelation with Hydroxamate in Histone Deacetylases Modulated by Water Access to the Linker Binding Channel. J. Am. Chem. Soc., 2011, 133 (16), 6110-6113
108. Bertrand, P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem., 2010, 45 (6), 2095-2116
109. Lombardi, P. M.; Cole, K. E.; Dowling, D. P.; Christianson, D. W. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol., 2011, 21 (6), 735-743
110. Cho, Y. S.; Whitehead, L.; Li, J.; Chen, C. H. T.; Jiang, L.; Vö gtle, M.; Francotte, E.; Richert, P.; Wagner, T.; Traebert, M. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J. Med. Chem., 2010, 53 (7), 2952-2963
111. Pabba, C.; Gregg, B. T.; Kitchen, D. B.; Chen, Z. J.; Judkins, A. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (1), 324-328
112. Marcaurelle, L. A.; Comer, E.; Dandapani, S.; Duvall, J. R.; Gerard, B.; Kesavan, S.; Lee IV, Liu, H.; Lowe, J. T.; Marie, J. C. An aldol-based build/couple/pair strategy for the synthesis of medium-and large-sized rings: Discovery of macrocyclic histone deacetylase inhibitors. J. Am. Chem. Soc., 2010, 132 (47), 16962-16976
113. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of Chimeric Histone Deacetylase-and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-R?, and Histone Deacetylases?. J. Med. Chem., 2009, 52 (8), 2265-2279
114. Suzuki, N.; Suzuki, T.; Ota, Y.; Nakano, T.; Kurihara, M.; Okuda, H.; Yamori, T.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J. Med. Chem., 2009, 52 (9), 2909-2922
115. Montero, A.; Beierle, J. M.; Olsen, C. A.; Ghadiri, M. R. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic ?/?-tetrapeptide architectures. J. Am. Chem. Soc., 2009, 131 (8), 3033
116. Olsen, C. A.; Ghadiri, M. R. Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic ?3?-Tetrapeptides. J. Med. Chem., 2009, 52 (23), 7836-7846
117. Zhang, Y.; Feng, J.; Liu, C.; Zhang, L.; Jiao, J.; Fang, H.; Su, L.; Zhang, X.; Zhang, J.; Li, M. Design, synthesis and preliminary activity assay of 1, 2, 3, 4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. Biorg. Med. Chem., 2010, 18 (5), 1761-1772
118. Zhang, Y.; Feng, J.; Jia, Y.; Wang, X.; Zhang, L.; Liu, C.; Fang, H.; Xu, W. Development of Tetrahydroisoquinoline-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in vitro and in vivo Antitumor Activities. J. Med. Chem., 2011, 54 (8), 2823-2838
119. Tang, W.; Luo, T.; Greenberg, E. F.; Bradner, J. E.; Schreiber, S. L. Discovery of histone deacetylase 8 selective inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (9), 2601-2605
120. Binaschi, M.; Boldetti, A.; Gianni, M.; Maggi, C. A.; Gensini, M.; Bigioni, M.; Parlani, M.; Giolitti, A.; Fratelli, M.; Valli, C. Antiproliferative and Differentiating Activities of a Novel Series of Histone Deacetylase Inhibitors. ACS Med. Chem. Lett., 2010,
121. Varasi, M.; Thaler, F.; Abate, A.; Bigogno, C.; Boggio, R.; Carenzi, G.; Cataudella, T.; Dal Zuffo, R.; Fulco, M. C.; Rozio, M. G.; Mai, A.; Dondio, G.; Minucci, S.; Mercurio, C. Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. J. Med. Chem., 2011, 54 (8), 3051-3064
122. Horne, W. S.; Olsen, C. A.; Beierle, J. M.; Montero, A.; Ghadiri, M. R. Probing the Bioactive Conformation of an Archetypal Natural Product HDAC Inhibitor with Conformationally Homogeneous Triazole-Modified Cyclic Tetrapeptides. Angew. Chem. Int. Ed., 2009, 48 (26), 4718-4724
123. Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Deschenes-Simard, B. t.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity. J. Med. Chem., 2010, 53 (23), 8387-8399
124. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton. J. Med. Chem., 2010, 53 (16), 6100-6111
125. Botta, C. B.; Cabri, W.; Cini, E.; De Cesare, L.; Fattorusso, C.; Giannini, G.; Persico, M.; Petrella, A.; Rondinelli, F.; Rodriquez, M.; Russo, A.; Taddei, M. Oxime Amides as a Novel Zinc Binding Group in Histone Deacetylase Inhibitors: Synthesis, Biological Activity, and Computational Evaluation. J. Med. Chem., 2011, 54 (7), 2165-2182
126. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc., 2010, 132 (31), 10842-10846
127. Spencer, J.; Amin, J.; Wang, M.; Packham, G.; Alwi, S. S. S.; Tizzard, G. J.; Coles, S. J.; Paranal, R. M.; Bradner, J. E.; Heightman, T. D. Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based Histone Deacetylase Inhibitors. ACS Med. Chem. Lett., 2011, 2 (5), 358-362
128. Wang, B.; Huang, P.-H.; Chen, C.-S.; Forsyth, C. J. Total Syntheses of the Histone Deacetylase Inhibitors Largazole and 2-epi-Largazole: Application ofN-Heterocyclic Carbene Mediated Acylations in Complex Molecule Synthesis. J. Org. Chem., 2011, 76 (4), 1140-1150
129. Thaler, F.; Colombo, A.; Mai, A.; Amici, R.; Bigogno, C.; Boggio, R.; Cappa, A.; Carrara, S.; Cataudella, T.; Fusar, F.; Gianti, E.; di Ventimiglia, S. J.; Moroni, M.; Munari, D.; Pain, G.; Regalia, N.; Sartori, L.; Vultaggio, S.; Dondio, G.; Gagliardi, S.; Minucci, S.; Mercurio, C.; Varasi, M. Synthesis and Biological Evaluation ofNHydroxyphenylacrylamides andN-Hydroxypyridin-2- ylacrylamides as Novel Histone Deacetylase Inhibitors. J. Med. Chem., 2010, 53 (2), 822-839
130. Kemp, M. M.; Wang, Q.; Fuller, J. H.; West, N.; Martinez, N. M.; Morse, E. M.; Weiwer, M.; Schreiber, S. L.; Bradner, J. E.; Koehler, A. N. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg. Med. Chem. Lett., 2011, 21 (14), 4164-9
131. Luo, Y.; Liu, H. M.; Su, M. B.; Sheng, L.; Zhou, Y. B.; Li, J.; Lu, W. Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (16), 4844-6
132. Ai, T.; Cui, H.; Chen, L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr. Med. Chem., 2012, 19 (4), 475-87
133. Blanquart, C.; Francois, M.; Charrier, C.; Bertrand, P.; Gregoire, M. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds. Curr. Cancer Drug Targets, 2011, 11 (8), 919-28
134. Jiaguo, H.; Zhiguo, L.; Wenbin, Z. Molecular probing and imaging of histone deacetylase inhibitors in cancer treatment. Anticancer Agents Med Chem, 2012, 12 (3), 182-6; (d)Pan, H.; Cao, J.; Xu, W. Selective histone deacetylase inhibitors. Anticancer Agents Med. Chem., 2012, 12 (3), 247-70